Substance P

The Systemic Effects of Substance P: A Comprehensive Overview

Substance P is a neuropeptide that functions as a neurotransmitter and neuromodulator within the central and peripheral nervous systems. This peptide is involved in numerous physiological and pathological processes, impacting pain perception, inflammation, cardiovascular and respiratory functions, gastrointestinal motility, immune response, mental health, and dermatological conditions. This article provides an in-depth look at the systemic effects of Substance P, supported by scientific references.

Pain Perception and Inflammation

Substance P is heavily implicated in the transmission of pain signals from peripheral receptors to the central nervous system. Elevated levels of Substance P are associated with increased pain perception and chronic pain conditions. Moreover, it promotes the release of pro-inflammatory cytokines and histamine, contributing to inflammation in conditions such as arthritis and fibromyalgia.

Cardiovascular Effects

Substance P induces vasodilation, which can lead to decreased blood pressure and increased blood flow to certain areas. It also affects heart rate and contractility, potentially influencing cardiovascular health.

Respiratory Effects

In the respiratory system, Substance P can cause bronchoconstriction, leading to the narrowing of the airways. This effect is particularly relevant in conditions like asthma and chronic obstructive pulmonary disease (COPD).

Gastrointestinal Effects

Substance P influences gastrointestinal motility and the secretion of digestive fluids, impacting conditions like irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Additionally, elevated levels of Substance P can trigger nausea and vomiting, often seen in chemotherapy-induced nausea .

Immune System Modulation

Substance P modulates immune responses by promoting the release of cytokines, impacting both acute and chronic inflammatory responses. It plays a significant role in neurogenic inflammation, where nerve stimulation causes an inflammatory response, contributing to conditions like migraines.

Mental Health and Neurological Effects

Altered levels of Substance P have been implicated in mood disorders, including depression and anxiety. Its role in neuroinflammation and neural communication also suggests involvement in neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.

Dermatological Effects

Substance P is involved in the regulation of skin inflammation and can exacerbate conditions like psoriasis and eczema. It influences the skin’s inflammatory response, contributing to various dermatological conditions.

Conclusion

Substance P is a key player in numerous physiological and pathological processes, making it a significant focus in medical research. Its systemic effects on pain perception, inflammation, cardiovascular and respiratory function, gastrointestinal motility, immune response, mental health, and dermatological conditions highlight its importance in understanding and developing treatments for various medical conditions.

References

1. Harrison, S., & Geppetti, P. (2001). Substance P. The International Journal of Biochemistry & Cell Biology, 33(6), 555-576.

2. Holzer, P. (1988). Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience, 24(3), 739-768.

3. Kopp, U. C., & Smith, L. A. (1993). Renal substance P release in response to substance P: effects of prostaglandins and nitric oxide. American Journal of Physiology-Renal Physiology, 264(5), F747-F756.

4. Tsuda, R., Hino, N., Mori, T., Takanari, H., & Itoh, T. (2001). Substance P release and coronary vasodilation in dogs. Heart and Vessels, 16(1), 16-21.

5. Barnes, P. J. (2001). Neurogenic inflammation in the airways. Respiratory Physiology, 125(1-2), 145-154.

6. O’Connor, T. M., O’Connell, J., O’Brien, D. I., Goode, T., Bredin, C. P., & Shanahan, F. (2004). The role of substance P in inflammatory disease. Journal of Cellular Physiology, 201(2), 167-180.

7. Holzer, P. (1998). Neurogenic vasodilatation and plasma leakage in the skin. General Pharmacology: The Vascular System, 30(1), 5-11.

8. Lai, J. P., Douglas, S. D., & Ho, W. Z. (1998). Human lymphocytes express substance P and its receptor. Journal of Neuroimmunology, 86(1), 80-86.

9. Stead, R. H., Tomioka, M., Quinonez, G., Simon, G. T., Felten, S. Y., & Bienenstock, J. (1987). Intestinal mucosal mast cells in normal and nematode-infected rats: cytochemistry, histochemistry, and microcirculation. The American Journal of Anatomy, 179(4), 331-341.

10. McLean, P. G., Coupar, I. M., & Shah, M. (1997). Effects of tachykinins on smooth muscle contractility in the rat isolated jejunum: a study using NK1- and NK2-receptor-selective agonists and antagonists. Naunyn-Schmiedeberg’s Archives of Pharmacology, 356(3), 343-349.

11. Mantyh, P. W., Rogers, S. D., Honore, P., Allen, B. J., Ghilardi, J. R., Li, J., ... & Vigna, S. R. (1997). Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science, 278(5336), 275-279.

12. Theodosis, D. T., & Poulain, D. A. (1984). Evidence for substance P as a transmitter of central trigeminal synapses: an electron microscopic study. Neuroscience, 11(3), 717-737.

13. Seegers, C. A., Claassen, V., Boonekamp, J. J., & Edwards, J. A. (1984). The role of substance P in neurogenic inflammation and immunity. Regulatory Peptides, 9(1-2), 87-102.

14. Groneberg, D. A., Harrison, S., Dinh, Q. T., Geppetti, P., & Fischer, A. (2006). Tachykinins in the respiratory tract. Current Drug Targets, 7(8), 1005-1011.